Terapevticheskii arkhivTerapevticheskii arkhivТерапевтический архив0040-36602309-5342LLC Obyedinennaya Redaktsiya31487Editorial articleПередовая статьяReview ArticleChoice of novel endpoints in clinical trials evaluating the efficiency of drug therapy in patients with pulmonary hypertensionВыбор новых "конечных точек" в клинических исследованиях, посвященных оценке эффективности лекарственной терапии у пациентов с легочной артериальной гипертониейAvdeevS NАвдеевС Нserg_avdeev@list.ruФГБУ "НИИ пульмонологии" ФМБА России, Москва15032014863VOL 86, NO3 ()ТОМ 86, №3 (2014)889310042020Copyright ©; 2014, Consilium MedicumCopyright ©; 2014, ООО "Консилиум Медикум"2014Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://ter-arkhiv.ru/0040-3660/article/view/31487

Pulmonary hypertension (PH) is characterized by a poor prognosis: the three-year survival rate in patients with PH is not greater than 60% as evidenced by current national registries. In the past decade, there have been drugs that are able to relieve symptoms of the disease, to slow down its progression, and improve quality of life. Historically, clinical trials dealing with PH have had a fixed and rather short-tern period and most commonly used the index "the change in the distance covered in the 6-minute walk test" as a primary endpoint. Further optimization of PH therapy requires that the efficacy of drugs and the strategies of therapy be evaluated with respect to their effects on morbidity and mortality, i.e. on prognosis. The SERAPHIN trial is now the only completed and published clinical trial using the combined index of morbidity and mortality as a primary endpoint. It demonstrates that that therapy with the novel drug macitentan causes a reduction in morbidity and mortality in patients with PH.

Аннотация. Легочная артериальная гипертония (ЛАГ) характеризуется неблагоприятным прогнозом; по данным современных национальных регистров, 3-летняя выживаемость пациентов с ЛАГ не превышает 60%. В течение последних 10 лет появи­лись лекарственные средства, способные уменьшить симптомы, улучшить качество жизни и замедлить прогрессирование заболевания. Исторически клинические исследования, посвященные ЛАГ, имели фиксированную и достаточно короткую продолжительность и чаще всего в качестве "первичной конечной точки" использовали такой показатель, как изменение пройденного расстояния в тесте с 6-минутной ходьбой. Для дальнейшей оптимизации терапии ЛАГ требуется оценка эффективности лекарственных средств и стратегий терапии с точки зрения их влияния на морбидность и летальность, т.е. на прогноз заболевания. В настоящее время единственным завершенным и опубликованным клиническим исследованием, в котором в качестве "первичной конечной точки" использован комбинированный показатель морбидности и летальности, является исследование SERAPHIN. В нем продемонстрировано, что терапия новым препаратом мацитентаном приводит к снижению морбидности и летальности у пациентов с ЛАГ.

pulmonary hypertensionstudy designendpointsmorbiditymortalitymacitentanлегочная артериальная гипертонияструктура исследований"конечные точки"морбидностьлетальностьмацитентанGaliè N., Hoeper M., Humbert M. et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Eur Heart J 2009; 30: 2493-2537.Galie N., Hoeper M.M., Humbert M. et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009; 34: 1219-1263.McLaughlin V.V., Archer S.L., Badesch D.B. et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation 2009; 119: 2250-2294.Humbert M., Sitbon O., Chaouat A. et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006; 173: 1023-1030.Peacock A.J., Murphy N.F., McMurray J.J.V. et al. An epidemiological study of pulmonary arterial hypertension. Eur Respir J 2007; 30: 104-109.Humbert M., Sitbon O., Yaïci A. et al. French Pulmonary Arterial Hypertension Network. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J 2010; 36: 549-555.Lee W.T., Ling Y., Sheares K.K. et al. Predicting survival in pulmonary arterial hypertension in the UK. Eur Respir J 2012; 40: 604-611.Benza R.L., Miller D.P., Gomberg-Maitland M. et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 2010; 122: 164-172.D'Alonzo G.E., Barst R.J., Ayres S.M. et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991; 115: 343-349.McLaughlin V.V. Prognosis of pulmonary arterial hypertension. The power of clinical registries of rare diseases. Circulation 2010; 122: 106-108.Preston I.R., Suissa S., Humbert M. New perspectives in long-term outcomes in clinical trials of pulmonary arterial hypertension. Eur Respir Rev 2013; 22: 495-502.Gomberg-Maitland M., Bull T.M. New trial designs and potential therapies for pulmonary artery hypertension. J Am Coll Cardiol 2013; 62: D82-91.Rubin L.J., Mendoza J., Hood M. et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med 1990; 112: 485-491.Barst R.J., Rubin L.J., Long W.A. et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 334: 296-302.Badesch D.B., Tapson V.F., McGoon M.D. et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000; 132: 425-434.Channick R.N., Simonneau G., Sitbon O. et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001; 358: 1119-1123.Rubin L.J., Badesch D.B., Barst R.J. et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896-903.Simonneau G., Barst R.J., Galiè N. et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165: 800-804.Langleben D., Christman B.W., Barst R.J. et al. Effects of the thromboxane synthetase inhibitor and receptor antagonist terbogrel in patients with primary pulmonary hypertension. Am Heart J 2002; 43: E4.Olschewski H., Simonneau G., Galiè N. et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347: 322-329.Galiè N., Humbert M., Vachiéry J.L. et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2002; 39: 1496-1502.Barst R.J., McGoon M., McLaughlin V. et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003; 41: 2119-2125.Humbert M., Barst R.J., Robbins I.M. et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 2004; 24: 353-359.Barst R.J., Langleben D., Frost A. et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004; 169: 441-447.Sastry B.K., Narasimhan C., Reddy N.K. et al. Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. J Am Coll Cardiol 2004; 43: 1149-1153.Wilkins M.R., Paul G.A., Strange J.W. et al. Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study. Am J Respir Crit Care Med 2005; 171: 1292-1297.Galiè N., Ghofrani H.A., Torbicki A. et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353: 2148-2157.Singh T., Rohit M., Grover A. et al. A randomized, placebo controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension. Am Heart J 2006; 151: 851.e1-e5.Barst R.J., Langleben D., Badesch D. et al. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol 2006; 47: 2049-2056.McLaughlin V.V., Oudiz R.J., Frost A. et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 2006; 174: 1257-1263.Hoeper M., Leuchte H., Halank M. et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2006; 4: 691-694.Galiè N., Beghetti M., Gatzoulis M.A. et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 2006; 114: 48-54.Galiè N., Rubin L.J., Hoeper M. et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 2008; 371: 2093-2100.Simonneau G., Rubin L.J., Galiè N. et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 2008; 149: 521-530.Galiè N., Olschewski H., Oudiz R.J. et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008; 117: 3010-3019.Galiè N., Brundage B.H., Ghofrani H.A. et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009; 119: 2894-2903.Hiremath J., Thanikachalam S., Parikh K. et al. Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial. J Heart Lung Transplant 2010; 29: 137-149.Ghofrani H.A., Morrell N.W., Hoeper M.M. et al. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med 2010; 182: 1171-1177.Jing Z.C., Yu Z.X., Shen J.Y. et al. Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study. Am J Respir Crit Care Med 2011; 183: 1723-1729.Sandoval J., Torbicki A., Souza R. et al. Safety and efficacy of sitaxsentan 50 and 100 mg in patients with pulmonary arterial hypertension. Pulm Pharmacol Ther 2012; 25: 33-39.Hoeper M.M., Barst R.J., Bourge R.C. et al. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation 2013; 127: 1128-1138.Ghofrani H.-A., Galiè N., Grimminger F. et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 2013; 369: 330-40.McLaughlin V.V., Badesch D.B., Delcroix M. et al. Endpoints and clinical trial design in pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54 (Suppl. 1): S97-S107.Fleming T.R., Powers J.H. Biomarkers and surrogate endpoints in clinical trials. Stat Med 2012; 31: 2973-2984.Frost A.E., Langleben D., Oudiz R. et al. The 6-min walk test (6MW) as an efficacy endpoint in pulmonary arterial hypertension clinical trials: demonstration of a ceiling effect. Vascul Pharmacol 2005; 43: 36-39.Gaine S., Simonneau G. The need to move from 6-minute walk distance to outcome trials in pulmonary arterial hypertension. Eur Respir Rev 2013; 22: 487-494.Savarese G., Paolillo S., Costanzo P. et al. Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials. J Am Coll Cardiol 2012; 60: 1192-1201.Gabler N.B., French B., Strom B.L. et al. Validation of 6-minute walk distance as a surrogate end point in pulmonary arterial hypertension trials. Circulation 2012; 126: 349-356.Ventetuolo C.E., Benza R.L., Peacock A.J. et al. Surrogate and combined end points in pulmonary arterial hypertension. Proc Am Thorac Soc 2008; 5: 617-622.Fleming T.R., Harrington D.P. Counting Processes and Survival Analysis. Wiley Series in Probability and Statistics. New York: Wiley 1991.Pulido T., Adzeriko I., Channick R. et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 2013; 369: 809-818.